Baxter International Inc.BAX
NYSE • Healthcare
$17.15
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-1254.0% YoY
Gross Margin
3068.0%
Health Score
2/10
D/E Ratio
1.55
Confidence
LOW
Business Snapshot
Baxter International Inc. is a global healthcare company operating in the Medical Instruments & Supplies industry on the NYSE, providing critical therapies and medical products including renal care, hospital products, and nutritional solutions. The company serves hospitals, clinics, and patients across more than 100 countries. Based on the available pricing data, the market capitalisation figure places the company in a tier that cannot be confirmed from the data provided, but the stock is trading at $17.15 — near its 52-week low of $15.73 and well below its 52-week high of $32.68, suggesting significant price deterioration over the past year.
Financial Health
Score: 2/10 Baxter's financial health presents serious concerns across nearly every dimension. The net margin stands at an alarming -851.0%, indicating the company is generating deeply negative earnings relative to revenue, while the gross margin figure of 3,068.0% appears anomalous and likely reflects a data distortion from asset sales or accounting adjustments rather than true operating economics...
Risk Assessment
- **FUNDAMENTAL DATA VACUUM:** P/E ratio, TTM revenue, and free cash flow are all unavailable, making standard security analysis impossible and materially elevating investment risk. - **REVENUE COLLAPSE:** Revenue growth of -1,254.0% YoY signals a catastrophic structural disruption to the company's reported financials, regardless of the underlying cause. - **PROFITABILITY:** Net margin of -851.0% indicates the company is deeply loss-making on a trailing twelve-month basis. - **TECHNICALS:** A confirmed death cross (50-day MA crossing below 200-day MA) combined with a bearish MACD signal reflects sustained downward price momentum, with the stock trading below both moving averages. - **ANALYST SENTIMENT:** Only 23% of analysts rate the stock a Buy, with 73% at Hold and the consensus formally rated as Sell — an unusually weak endorsement from Wall Street....